Literature DB >> 30981602

NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.

Ahmed Elsada1, Amanda I Adler2.   

Abstract

Entities:  

Year:  2019        PMID： 30981602     DOI： 10.1016/S1470-2045(19)30222-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

Authors:  Ahmed Elsada; Amy Zalin-Miller; Craig Knott; Leonidas Caravotas
Journal:  EJHaem       Date:  2021-06-10

2.  A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.

Authors:  Li Liu; Michael R Shurin; Sarah E Wheeler
Journal:  Clin Biochem       Date:  2019-11-11       Impact factor: 3.281

3.  CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment.

Authors:  Ying Zhu; Zhigang Zhang; Zhou Jiang; Yang Liu; Jianwei Zhou
Journal:  Front Genet       Date:  2020-04-30       Impact factor: 4.599
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.